Ann: Trading Halt, page-29

Presumably, we have found another product which we can progress to commercialisation promptly. While there will almost certainly be short-term pain and SP decompensation, the medium-term potential of two revenue streams (S Bromide and another) to fund our own product testing and development work would be a significant strength. Also, getting multiple products through a standard or fast-tracked approvals process in (perhaps) several countries will ensure we have a track record and recent experience (further to Vince's background) to help get our products through efficiently post- Ph3. CRs are unsettling, but let's await the detail by Monday. GLTA